Corporate | Regen Lab

RegenLab Welcomes OSP & SHE Delegation to BioArk Tech Park

par Marc Antoine Aimé | Juin 22, 2026 | Corporate

Education, Innovation and Regenerative Medicine: RegenLab Welcomes OSP (Office d’orientation scolaire, professionnelle et de carrière) & SHE (Service des hautes écoles ) Delegation to BioArk Tech Park ; Strengthening connections between education, innovation and...

RegenLab and MSFpharm Strengthen Their Partnership with a Scientific Event in Belgrade

par Marc Antoine Aimé | Juin 10, 2026 | Congress, Corporate

RegenLab and MSFpharm Strengthen Their Partnership with a Scientific Event in Belgrade From Regeneration to Collagen Stimulation: Advanced Clinical Applications of RegenLab BCT & Cellular Matrix will take place on 27 June 2026, bringing together expert faculty, live...

RegenLab USA & MiMedx: Exclusive U.S. Distribution for RegenKit®-Wound Gel

par Marc Antoine Aimé | Jan 13, 2026 | Corporate

RegenLab USA and MiMedx Announce Exclusive U.S. Distribution Agreement for RegenKit®-Wound Gel ; “We are thrilled to partner with MIMEDX to bring RegenKit®-Wound Gel to patients across the United States, » said Franck Maingonnat, VP of Business Development at Regen...

PRP Preparation in Europe | CE Marking, Safety & Standardisation

par Marc Antoine Aimé | Jan 6, 2026 | Corporate

See why the Regenlab patented system is not just another tube Closed-System PRP Preparation: Improving Safety and Standardisation in Clinic ; In daily practice, not all tubes are equivalent when it comes to preparing PRP (Platelet-Rich Plasma). Beyond appearance, the...

ESSM-REGENLAB Webinar Series #2

par Marc Antoine Aimé | Juin 30, 2025 | Corporate

The replay of the ESSM Webinar Series 2024 session, hosted in collaboration with RegenLab, is now available to watch. Female regenerative therapies. State of the art. Watch replay  Moderators Giovanni CoronaMD PhDEndocrinology Unit Prof Dr Daniar...

RegenLab USA Opens New R&D and Manufacturing Facility in Jersey City

par Marc Antoine Aimé | Juin 17, 2025 | Corporate

RegenLab USA Opens New R&D and Manufacturing Facility in Jersey City Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to...

« Entrées précédentes



RegenPRP™

RegenPRP™ is a medical treatment that uses platelet-rich plasma from the patient's own blood to enhance and tissue regeneration.



RegenPRP™ - HA

RegenPRP™ - HA combination is an innovative treatment combining platelet-rich plasma (PRP) and hyaluronic acid to improve tissue regeneration and healing.

CM-OA

CM-Skin



RegenPRP™ - ATS

RegenPRP™ combined with ATS (Autologous Thrombin Serum) is an advanced approach to tissue regeneration that uses autologous thrombin-enriched platelet-rich plasma (PRP) to maximise healing effects.



RegenExtracell®

RegenExtracell is an innovative tissue regeneration treatment using an extracellular matrix enriched with platelet-rich plasma (PRP).



RegenWound

RegenWound is a fully autologous solution prepared from the patient’s own blood, with the objective of providing a standardised and reproducible approach for clinical use.



Regulatory

Manufacturers of medical devices based outside the EU must designate an Authorized Representative (EU-REP) established within the EU in order to meet the CE requirements for placing medical devices on the EU market.



Quality Management

Regen Lab Quality System Management ensures the consistency of our products quality in total GMP compliance.

Our production facility rooms atmosphere is monitored to satisfy non-pyrogenic medical devices manufacturing.



Patents

As a leader in the PRP&HA regenerative field and as an innovation-driven company, Regen Lab SA has devoted important resources since 2004 to put on the market pioneering and diversified products constituting a complete set of tools/technologies for the medical community.